137 related articles for article (PubMed ID: 35552245)
1. Correlation of
Duan H; Baratto L; Fan RE; Soerensen SJC; Liang T; Chung BI; Thong AEC; Gill H; Kunder C; Stoyanova T; Rusu M; Loening AM; Ghanouni P; Davidzon GA; Moradi F; Sonn GA; Iagaru A
J Nucl Med; 2022 Dec; 63(12):1829-1835. PubMed ID: 35552245
[No Abstract] [Full Text] [Related]
2. A Pilot Study of
Duan H; Ghanouni P; Daniel B; Rosenberg J; Thong A; Kunder C; Aparici CM; Davidzon GA; Moradi F; Sonn GA; Iagaru A
J Nucl Med; 2023 May; 64(5):744-750. PubMed ID: 36396456
[TBL] [Abstract][Full Text] [Related]
3. A Pilot Study of
Duan H; Ghanouni P; Daniel B; Rosenberg J; Davidzon GA; Aparici CM; Kunder C; Sonn GA; Iagaru A
J Nucl Med; 2023 Apr; 64(4):592-597. PubMed ID: 36328488
[TBL] [Abstract][Full Text] [Related]
4. Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer.
Touijer KA; Michaud L; Alvarez HAV; Gopalan A; Kossatz S; Gonen M; Beattie B; Sandler I; Lyaschenko S; Eastham JA; Scardino PT; Hricak H; Weber WA
Eur Urol Oncol; 2019 Mar; 2(2):166-173. PubMed ID: 31017093
[TBL] [Abstract][Full Text] [Related]
5. Value of
Beheshti M; Taimen P; Kemppainen J; Jambor I; Müller A; Loidl W; Kähkönen E; Käkelä M; Berndt M; Stephens AW; Minn H; Langsteger W
Eur Radiol; 2023 Jan; 33(1):472-482. PubMed ID: 35864350
[TBL] [Abstract][Full Text] [Related]
6. Incremental Impact of [
Szigeti F; Schweighofer-Zwink G; Meissnitzer M; Hauser-Kronberger C; Hitzl W; Kunit T; Forstner R; Pirich C; Beheshti M
Mol Imaging Biol; 2022 Feb; 24(1):50-59. PubMed ID: 34519966
[TBL] [Abstract][Full Text] [Related]
7. Prospective Evaluation of
Minamimoto R; Sonni I; Hancock S; Vasanawala S; Loening A; Gambhir SS; Iagaru A
J Nucl Med; 2018 May; 59(5):803-808. PubMed ID: 29084827
[No Abstract] [Full Text] [Related]
8. Comparison of
Schollhammer R; Robert G; Asselineau J; Yacoub M; Vimont D; Balamoutoff N; Bladou F; Bénard A; Hindié E; Gallerande HC; Morgat C
J Nucl Med; 2023 Mar; 64(3):379-385. PubMed ID: 36215569
[TBL] [Abstract][Full Text] [Related]
9. PSMA- and GRPR-Targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer.
Baratto L; Song H; Duan H; Hatami N; Bagshaw HP; Buyyounouski M; Hancock S; Shah S; Srinivas S; Swift P; Moradi F; Davidzon G; Iagaru A
J Nucl Med; 2021 Nov; 62(11):1545-1549. PubMed ID: 33674398
[TBL] [Abstract][Full Text] [Related]
10. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and
Franklin A; Yaxley WJ; Raveenthiran S; Coughlin G; Gianduzzo T; Kua B; McEwan L; Wong D; Delahunt B; Egevad L; Samaratunga H; Brown N; Parkinson R; Roberts MJ; Yaxley JW
BJU Int; 2021 Jan; 127(1):71-79. PubMed ID: 32524748
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist
Wieser G; Popp I; Christian Rischke H; Drendel V; Grosu AL; Bartholomä M; Weber WA; Mansi R; Wetterauer U; Schultze-Seemann W; Meyer PT; Jilg CA
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1463-1472. PubMed ID: 28417160
[TBL] [Abstract][Full Text] [Related]
12.
Duan H; Moradi F; Davidzon GA; Liang T; Song H; Loening AM; Vasanawala S; Srinivas S; Brooks JD; Hancock S; Iagaru A
Lancet Oncol; 2024 Apr; 25(4):501-508. PubMed ID: 38423030
[TBL] [Abstract][Full Text] [Related]
13. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
14. How accurate is
Erdem S; Simsek DH; Degirmenci E; Aydin R; Bagbudar S; Ozluk Y; Sanli Y; Sanli O; Ozcan F
Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066
[TBL] [Abstract][Full Text] [Related]
15. PET Imaging Using Gallium-68 (
Duan H; Iagaru A
PET Clin; 2022 Oct; 17(4):621-629. PubMed ID: 36153233
[TBL] [Abstract][Full Text] [Related]
16. Gallium 68 PSMA-11 PET/MR Imaging in Patients with Intermediate- or High-Risk Prostate Cancer.
Park SY; Zacharias C; Harrison C; Fan RE; Kunder C; Hatami N; Giesel F; Ghanouni P; Daniel B; Loening AM; Sonn GA; Iagaru A
Radiology; 2018 Aug; 288(2):495-505. PubMed ID: 29786490
[TBL] [Abstract][Full Text] [Related]
17. Pilot Comparison of ⁶⁸Ga-RM2 PET and ⁶⁸Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer.
Minamimoto R; Hancock S; Schneider B; Chin FT; Jamali M; Loening A; Vasanawala S; Gambhir SS; Iagaru A
J Nucl Med; 2016 Apr; 57(4):557-62. PubMed ID: 26659347
[TBL] [Abstract][Full Text] [Related]
18. Accuracy of [
Fassbender TF; Schiller F; Mix M; Maecke HR; Kiefer S; Drendel V; Meyer PT; Jilg CA
Nucl Med Biol; 2019 Mar; 70():32-38. PubMed ID: 30836254
[TBL] [Abstract][Full Text] [Related]
19. Pilot study of the diagnostic utility of
Vlachostergios PJ; Niaz MJ; Thomas C; Christos PJ; Osborne JR; Margolis DJA; Khani F; Bander NH; Scherr DS; Tagawa ST
Prostate; 2022 Mar; 82(4):483-492. PubMed ID: 34985786
[TBL] [Abstract][Full Text] [Related]
20. Head-to-Head Comparison of
Sonni I; Felker ER; Lenis AT; Sisk AE; Bahri S; Allen-Auerbach M; Armstrong WR; Suvannarerg V; Tubtawee T; Grogan T; Elashoff D; Eiber M; Raman SS; Czernin J; Reiter RE; Calais J
J Nucl Med; 2022 Jun; 63(6):847-854. PubMed ID: 34649942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
